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Introduction
The integrity of all gene expression is reliant on RNA, and the 
property of nucleic acids that permits complementary base pairing 
has long been an attractive option to alter gene expression by 
modulating RNA structure, function or abundance to treat human 
disease. Advances in the field have been predicated upon devel-
opment of synthetic nucleic acid analogues (for review, see 1) 
that resist nuclease degradation and can be modified to evoke 
specific mechanisms. An antisense (the reverse complement) 
nucleic acid sequence (oligonucleotide) to a region of the target 
molecule can be designed and evaluated in a routine manner to 
identify compounds with the required specificity and affinity 
to alter the abundance, structure or functionality of the resulting 
transcript (Figure 1). Such outcomes have far-reaching poten-
tial to alter the course of human diseases, and at this time, the 
indications are mostly rare inherited conditions with otherwise 
limited treatment options. The field has attracted some debate 
regarding the high treatment costs, clinical trial and regulatory 
evaluation outcomes and approvals, some uncertainty regarding 
mechanisms of action1 and emerging reports of off-target 
effects2,3. Although only a small number of antisense drugs 
are in the clinic4 or undergoing translation at this time, ongoing 
efforts to improve oligonucleotide drug delivery and efficacy 
and to better understand antisense mechanisms will drive further 
advances in the field.
Natural nucleic acids are biologically labile and their applica-
tion in drug development has required chemical modifications 
of the bases and nucleic acid backbone to increase resistance to 
endogenous nucleases and influence activity. The phosphorothio-
ate backbone is the most widely applied chemical modification 
(Figure 2), and although the substitution of sulphur for a 
Figure 1. Currently approved antisense oligonucleotide drugs, indicating chemistry and mechanisms of action. Antisense strategies 
that induce transcript degradation (left panel) include RNaseH degradation of the target transcript, activated by annealing of a complementary 
oligodeoxynucleotide (A) and transcript degradation by small interfering RNA (siRNA) (B). Transcript modification by RNA analogues (right 
panel) can be achieved by targeting splice motifs to exclude an exon to alter the reading frame or remove exons carrying mutations (C) 
or strengthen exon selection, otherwise compromised by base changes (D). 2′-O-MOE, 2′-O-(2-methoxyethyl); DMD, dystrophin; ISS-N1, 
intron splice silencer N1; PMO, phosphorodiamidate morpholino oligomer; PO, phosphodiester; PS, phosphorothioate; RISC, RNA-induced 
silencing complex; SMN2, survival motor neuron 2.
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non-bridging oxygen confers nuclease stability, changes to 
the ribose moiety can confer RNA-like characteristics and 
hydrophobicity to the oligonucleotide (for example, 2′-O-methyl, 
2′-O-methoxyethyl and 2′-O-fluoro). Phosphorothioate oligo-
nucleotides carry a strong negative charge, allowing binding 
to various proteins and complex formation with cationic 
liposomes for efficient transfection in vitro. Other nucleobase and 
backbone modifications can confer specific characteristics and 
mechanisms of action, and include peptide nucleic acids and 
phosphorodiamidate morpholino oligomers (PMOs) (Figure 2) 
that carry a neutral charge but show inefficient cellular uptake 
(for review, see 5).
The more widely exploited antisense strategies use DNA ana-
logues that activate RNase H1 degradation of the target transcript 
(Figure 1), and thereby downregulate gene expression, or double- 
stranded RNAs to induce gene silencing, comprehensively 
reviewed by Shen and Corey6. The concept of altering splice site 
selection to modify disease-causing transcripts was validated 
in vitro over 25 years ago7 and requires the design and applica-
tion of an RNA analogue that targets motifs participating in exon 
selection and retention in the mature mRNA. Antisense targeting 
of splice sites or motifs necessary for exon selection can 
influence endogenous alternative splicing, block aberrant splicing, 
exclude a cryptic exon or an exon carrying a disease-causing 
mutation, or restore the open reading frame around a frame- 
shifting deletion, whereas targeting splicing silencers can enhance 
selection of an exon, otherwise compromised by nucleotide 
changes (for reviews, see 8,9).
At this time, two mRNA splice-modulating drugs are reported 
to have delivered therapeutic benefit to a subset of patients with 
Duchenne muscular dystrophy (DMD)10 and to patients with 
spinal muscular atrophy (SMA)11. Eteplirsen (Exondys51), 
Sarepta Therapeutics, Cambridge, MA, USA) is an antisense 
PMO that targets splice enhancer motifs in the DMD pre-mRNA 
to exclude exon 51 and restore the dystrophin mRNA reading 
frame, disrupted by most deletions beginning at exon 52 or end-
ing at exon 50. Eteplirsen received accelerated approval from the 
US Food and Drug Administration (FDA) in September 2016 but 
is not yet approved in Europe. The drug nusinersen (Spinraza ®, 
Biogen, Cambridge, MA, USA) for the treatment of SMA is a 
2′-O-methoxyethyl antisense oligonucleotide (AO) on a phos-
phorothioate backbone. Nusinersen targets a splice silencer 
(ISS-N1) in survival motor neuron 2 (SMN2) intron 7 and pro-
motes exon 7 selection and retention during pre-mRNA splicing12 
and was approved by the FDA in December 2016. The roughly 
25-year history of antisense drug development parallels that 
of an increasing interest in therapeutics for rare diseases. 
Of patients with any of the more than 6,000 rare diseases 
Figure 2. Natural and chemically modified nucleotides. Upper panel: DNA, RNA and phosphorothioate (sulphur substituted for a non-
bridging oxygen)-modified nucleotide (PS DNA). Lower panel: 2′-O-methyl phosphorothioate (2′-OMePS), 2′-O-methoxyethyl phosphorothioate 
(2′-O-MOE-PS) and phosphorodiamidate morpholino oligomer (PMO).
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described to date, only a few groups of patients benefit from 
an effective treatment. It is perhaps fitting that the first splice 
intervention antisense therapeutics to reach the clinic address 
two of the more common and debilitating of the life-limiting 
inherited rare diseases of childhood. This review focuses on 
the development and current status of AO drugs that alter exon 
selection and exert a therapeutic effect by restoring or altering 
protein structure and function.
RNA splice-modulating drugs in the clinic
The field of RNA splicing therapeutics was launched by the 
demonstration of AO-mediated suppression of a disease- 
causing cryptic splice site in the β-globin transcript in a cell-free 
system7. This was followed by parallel programs to develop RNA 
therapeutics to alter exon selection during processing of the dys-
trophin (DMD) pre-mRNA and generate internally truncated 
but functional dystrophin isoforms that reflect variants found 
in the less severe allelic disorder, Becker muscular dystrophy 
(for review, see 13). Over 60% of the DMD-causing mutations 
are deletions of one or more exons, predominantly between 
exons 43 and 53 (major deletion hotspot) or exons 3 and 7 (minor 
deletion hotspot), that disrupt the translational reading frame and 
yield a prematurely truncated, non-functional protein. Becker 
muscular dystrophy is less common and is the consequence 
of mutations that yield a protein of reduced function or 
abundance or both. Becker muscular dystrophy mutations are 
generally in-frame deletions and provide “templates” for partially 
functional dystrophin variants that could ameliorate the severe 
dystrophic muscle phenotype characteristic of DMD. While the 
dystrophin exon-skipping programs aimed to develop antisense 
oligomer sequences that prevent exon selection during dys-
trophin pre-mRNA splicing (exon skipping) to generate internally 
truncated dystrophin molecules, two different RNA-like analogue 
chemistries were used for translational development. 
Antisense treatment to restore dystrophin expression
Two experimental antisense drugs, both designed to treat DMD 
in a subset of patients by removing dystrophin exon 51 and 
re-frame the transcript around disease-causing deletions that 
flank exon 51, such as exon 50, exons 48 to 50 or exon 52, were 
evaluated in independent clinical trials and presented for regula-
tory consideration in 2015. The investigational drug drisapersen, 
a 2′-O-methyl–modified AO on a phosphorothioate back-
bone, was evaluated in 186 ambulant participants with DMD 
by using subcutaneous injections at a dosage of 6 mg/kg per 
week in an extended study over the course of 188 weeks14. 
Although the drug was reported to be generally well tolerated14, 
renal effects, thrombocytopenia and injection site reactions 
have attracted attention15. Drisapersen failed to meet primary 
and secondary endpoints and, in light of the considerable 
adverse side effects, was withdrawn from further development 
after negative feedback from the regulators. (For comprehen-
sive review of antisense therapeutics for neuromuscular disease, 
see 16.) Injection site reactions and skin abnormalities as a 
consequence of long-term subcutaneous drisapersen injection 
remain unresolved even long after cessation of treatment15,17.
Eteplirsen is a PMO delivered by once-weekly intravenous infu-
sion (30 mg/kg) that also targets dystrophin exon 51 and received 
accelerated approval from the FDA in 2016. The approval of 
eteplirsen evoked lively discussion18–21 largely because of the 
small study group; use of a trial structure that had the placebo 
cohort transition to treatment after 6 months, when the differ-
ence in ambulation, the primary endpoint, reached significance; 
and the low (relative to healthy) levels of muscle dystrophin 
induced by the treatment10. In the aftermath of FDA review and 
concern regarding the efficacy of eteplirsen, much attention 
focused on dystrophin quantitation and clinical trial outcome 
measures. However, seven years after initiation of Sarepta 
Therapeutics study 201 and completion of the extension study 
202 (long-term safety and efficacy), the trial participants receiving 
eteplirsen continue to show functional benefits, respiratory 
function decline is half that expected from the natural history of 
the disease22, and no treatment-related serious adverse events have 
been reported. Class II evidence of increased dystrophin expres-
sion over baseline dystrophin was presented23, and although 
the treatment regimen is costly (more than $300,000 per year 
for a 25-kg child; for review, see 24) and the weekly intrave-
nous treatment regimen can be burdensome for patients and their 
families, continued ambulation in teenage patients with DMD10, 
together with respiratory benefits22, represents a marked devia-
tion from the natural history of the disease, is unprecedented and 
sets a benchmark for future dystrophin-restoring therapies.
Spinal muscular atrophy
SMA is a recessive disease characterized by deficiency of 
SMN protein that leads to the selective loss of spinal motor 
neurons and skeletal muscle paralysis, affecting the trunk 
and limbs. SMA is the most common genetic cause of infant 
mortality with a prevalence of 1 in about 11,000 live births and 
carrier frequency of 1 in 40 to 67, depending on ethnicity25. The 
genetic defect in 95% of cases is homozygous deletion of the 
SMN1 gene and while the SMN2 gene, present in all patients 
with SMA, potentially encodes an identical protein, a syn-
onymous C>T variant in exon 7 leads to aberrant processing 
of the mRNA. SMN2 copy number is polymorphic, and there 
is some inverse correlation between the number of copies of 
SMN2 and disease severity. An AO targeting an intronic splice 
silencer motif, ISS-N112, increased full-length SMN transcript in 
pre-clinical studies, and the 2′-O-methoxyethyl phosphorothio-
ate AO was approved under the name spinraza after a randomized 
placebo-controlled clinical trial. The patients who received 
intrathecal injection of nusinersen (12 mg) showed increased 
event-free survival and significant improvements in motor func-
tion, not seen in patients with SMA type 111, prompting early 
termination of the study26. Comprehensive review and analysis 
of nusinersen treatment in SMA by the Canadian Agency for 
Drugs and Technologies in Health include commentary on the 
cost-benefit (at a cost of $708,000 in year 1 for four treatments 
of 12 mg and $354,000 annually for maintenance treatments 
thereafter)27. Nusinersen is now available in many European 
countries, the USA, Canada, Australia, New Zealand and Japan 
and is reported to deliver clinical benefit in both SMA type 1 and 
type 2 patients28.
Splice-modifying therapies under development
Pre-clinical and clinical studies on novel splice-modulating 
experimental drugs are gaining momentum. (For review of 
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splice-modifying oligonucleotides under development, see 9.) 
Current strategies include dystrophin exon-skipping programs, 
exons 45 casimersen (SRP-4045) and 53 golodirsen (SRP-4053) 
by Sarepta Therapeutics (https://www.sarepta.com/pipeline/
exon-skipping-duchenne); an unrelated dystrophin exon 53 
program29,30; exon-skipping strategies to treat dysferlinopa-
thies (for example, limb girdle muscular dystrophy type 2B) 
by excluding exons 37 and 38 in a Dysf mutant mouse model; 
targeting cryptic exons activated by deep intronic mutations 
causing choroideremia31, Leber congenital amaurosis32 and USH2A-
associated retinal degeneration33; correction of mis-splicing of har-
monium in USH1C and exon inclusion to address a common splice 
variant causing adult-onset Pompe disease34. Two different 
exon-skipping strategies to treat spinocerebellar ataxia type 3 
were recently reported. The pathogenic expanded polyglutamine 
repeat can be removed by skipping exon 1035; however, in an 
innovative strategy, exons 8 and 9 were skipped in order to 
prevent proteolytic cleavage and generation of toxic protein 
fragments36.
Though not widely exploited, modulation of endogenous alter-
native splicing to alter isoform ratios could have broad appli-
cability to a number of acquired and inherited phenotypes. 
AO-mediated switching of Bcl-x splicing from the anti-apoptotic 
isoform to the pro-apoptotic isoform induced apoptosis of glioma 
cell lines37 and of hepatic stellate cells in liver fibrosis studies38. 
Endogenous aberrant splicing of GNB3 was corrected by AO-
mediated splice intervention39. The LMNA gene encodes two 
alternatively spliced products that are major components of 
the nuclear envelope. Mutations in the pre-lamin A transcript 
can result in aberrant splicing, causing Hutchison–Gilford prog-
eria syndrome that can be addressed either by AO targeting of the 
cryptic splice site (for review, see 40) or by manipulating 
splicing of exon 11 to favour the lamin C isoform41.
Although development of novel molecular therapeutics is 
eagerly anticipated by patients and families and has instigated 
efforts to find new targets and intervention opportunities, current 
limitations to broader applicability need to be overcome, 
primarily inefficient delivery to target tissues. The charge-neutral 
PMOs have an excellent safety profile but are rapidly cleared 
from the circulation, showing poor uptake into cells. Pre-clini-
cal development of exon-skipping PMOs in a mouse muscular 
dystrophy model showed moderate restoration of skeletal 
muscle dystrophin but minimal uptake in the myocardium42. 
Systemic delivery of these molecules can be greatly improved by 
conjugation to cell-penetrating peptides43,44, the use of novel 
strategies, such as exploiting exosomes and targeting peptides45, 
and gaining greater insights into the mechanisms of cell 
uptake46. Successful translation of peptide-phosphorodiamidate 
morpholino drugs that are currently in development and clini-
cal evaluation (for example, for DMD) may well begin a new 
era for splice-modifying therapies, particularly if tissue or cell 
targeting can be achieved, perhaps leading to reduced dosages.
Non-antisense and off-target effects of synthetic 
oligonucleotides
Oligonucleotide backbone and sugar modifications influence 
resistance to nucleases, mechanism of action, tissue distribution 
and binding to various proteins but can also cause hybridization- 
dependent (off-target hybridization of RNase H1-competent 
AOs resulting in hepatotoxicity47) and independent effects. 
Phosphorothioate oligonucleotides administered in vivo bind 
to serum and cellular proteins2,48 (for review, see 49) and show 
good tissue uptake and distribution, in the brain in particular50. 
However, in a systematic literature review of original trial 
reports, by van Meer et al.51, all studies involving phospho-
rothioate oligonucleotides administered subcutaneously report 
injection site reactions, while intravenous delivery was associ-
ated with thrombocytopenia. Phosphorothioate oligonucleotide 
sequences were reported to be immunostimulatory52 and to 
bind to platelets, eliciting strong platelet-activating effects53, 
while intracerebroventricular injection of 2′-O-methyl phospho-
rothioate AOs upregulated immune system-associated genes50. 
More recently, antisense drugs include modifications to enhance 
affinity (for example, locked nucleic acids or constrained ethyl 
substituted gapmers) that are reported to cause hepatotoxicity 
due to off-target RNA hybridization and downregulation47,54. 
In an elegant study, Dieckmann et al.54 showed that hybridiza-
tion-dependent toxicity of RNase H1-competent phosphorothioate 
oligonucleotides can be mitigated by limiting the affinity of the 
oligonucleotide and improving target specificity.
The propensity for phosphorothioate oligonucleotides to cause 
injection site reactions15,17, flu-like symptoms, and hepatotox-
icity was well known prior to the drisapersen exon-skipping 
studies and was reported in patients who received the approved 
drug mipomersen (RNase H1-competent gapmer) for the treatment 
of homozygous hypercholesteremia55,56.
Although the hepatotoxicity may be attributable in part to 
off-target hybridization, the exact cause of the injection site 
reactions remains unknown. Shen et al.57 examined cells trans-
fected with phosphorothioate oligonucleotides with various 
2′ modifications. They found that these compounds bind a large 
number of intracellular proteins and can replace the architec-
tural long non-coding RNA NEAT1 in subnuclear bodies called 
paraspeckles. The repertoire of proteins bound by phosphorothioate 
AOs and the effects of protein depletion or altered cellular local-
ization are influenced by any 2′ modification58. The most widely 
used modification, 2′-O-methoxyethyl, was found to have an 
acceptable tolerability profile and consistent behaviour between 
sequences3, whereas 2′-fluoro-modified phosphorothioate oli-
gonucleotides disturb nuclear biology, impair cell proliferation 
and cause loss of cellular proteins59.
We explored the interaction of 2′-O-methyl phosphorothioate 
AOs with nuclear proteins and report backbone-specific effects 
of modified oligonucleotides on subnuclear organelles, altered 
distribution of nuclear proteins, the appearance of novel large 
structured nuclear inclusions, modification of RNA processing 
and marked disturbance of the transcriptome in cultured cells. 
We speculate that some side effects and adverse events reported 
after clinical evaluation of phosphorothioate nucleic acid drugs 
may be mediated, at least in part, by non-specific interaction 
of nuclear components with the phosphorothioate backbone60. 
The sequence-independent effects of phosphorothioate com-
pounds indeed may enhance or confound apparent antisense 
Page 6 of 11
F1000Research 2019, 8(F1000 Faculty Rev):710 Last updated: 22 MAY 2019
effects61 as a consequence of extensive disturbance of nuclear 
proteins and organelles, particularly those critical for RNA 
processing and splicing. Strategies to reduce cellular protein 
binding by phosphorothioate AOs and mitigate toxic effects, 
thereby improving the therapeutic profile of these molecules by 
backbone62 and 2′-O-modifications63 are important steps in 
guiding AO design. Other considerations that may warrant 
comprehensive investigation are whether phosphorothioate 
nucleotide degradation products are incorporated into cellular 
nucleic acids, a question that has been raised64, and whether the 
immune activation by intra-cerebroventricular injection of a 
2′-O-methyl phosphorothioate AO reported in mice50 should be 
of concern in humans who receive similar compounds.
Molecular medicines in the future
In an era of promising gene replacement and gene correction 
strategies, exploiting novel recombinant viruses that can be 
selected and tailored for tropism to specific tissues, the rationale 
for pursuing transcript-modifying therapies might be ques-
tioned. Many of these emerging molecular and gene therapeutics 
target rare and life-limiting diseases caused by multiple gene 
variants that may show variable progression and phenotypes 
within one patient group and, in the event that more than one treat-
ment modality is investigated, compete for the same restricted 
patient population in recruiting clinical trial participants.
However, consider the situation where different treatment 
modalities could be used in tandem. For example, an antisense 
strategy might be the only option following vector gene delivery 
if the virus results in seroconversion and precludes re-delivery. 
PMOs designed to alter exon selection are specific to the 
target transcript and, to the best of our knowledge, have not 
been reported to cause off-target effects on splicing and have 
no effect when delivered to cells lacking the target transcript. In 
the case of cryptic exon or aberrant splice site usage, antisense- 
mediated strategies can generate a normal product, unlikely to be 
immunogenic, that is expressed under endogenous, tissue/cell/ 
developmental regulation. Gain-of-function mutations may 
be particularly amenable to splice interventions, whereas for 
loss-of-function mutations, splice variants can be designed to 
encode products that may exhibit reduced function but could 
ameliorate otherwise severe disease.
We conclude by acknowledging the contribution of the patients 
and the combined efforts of chemists, researchers and clinicians 
and those in the biopharmaceutical industry who championed 
these drugs and the insightful regulators who have yielded two 
splice interventions, now available to patients. Although there 
is general agreement that better drug uptake and greater efficacy 
are desirable, these drugs, by all accounts, are altering the 
course of previously untreatable disease. There is potential for 
numerous therapeutics in the “splice modulating” class. The 
lessons learnt over the course of translating eteplirsen and 
nusinersen and from the failure of drispersen will inform the 
development of emerging and future molecular medicines.
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